Predictors of responses to immune checkpoint blockade in advanced melanomaNicolas Jacquelot, Laurence Zitvogel, Abhishek Burra et al.|Nature Communications|2017Cited by 201
Evolving treatments and outcomes in HER2-Positive metastatic breast cancer: Data from the GIM14/BIOMETA studyMassimo Di Maïo, Grazia Arpino, Claudia Bighin et al.|The Breast|2023Cited by 9
Luminal-like HER2-negative stage IA breast cancer: a multicenter retrospective study on long-term outcome with propensity score analysisCarmine De Angelis, Grazia Arpino, Massimo Di Maïo et al.|Oncotarget|2017Cited by 3
The use of bone-modifying agents in early breast cancer: AIOM Guidelines update and perspectivesStefania Gori, Riccardo Gerosa, Michela Cinquini et al.|Tumori Journal|2025Cited by 1
List of ContributorsEliana Abdelhay, Farhadul Islam, Pavan P. Adiseshaiah et al.|Elsevier eBooks|2018Cited by 0